TenNor reported positive top‑line results from a Phase IIa proof‑of‑concept trial of rifaquizinone (TNP‑2092) for periprosthetic joint infection in China. Seven of ten patients were evaluation‑eligible; all five early/acute cases that completed six months were successful, and four remained successful at 12 months. In the chronic cohort, one of two patients achieved six‑month success; 12‑month chronic data are pending. No TNP‑2092‑related TEAEs or SAEs were attributed in the safety set, and a multi‑centre Phase IIb has been launched after NMPA approval.
TenNor Reports Promising Phase IIa Results for TNP‑2092 (Rifaquizinone) in Periprosthetic Joint Infection
The study focused on early
TenNor Therapeutics announced encouraging top-line data from a Phase IIa proof-of-concept trial evaluating rifaquizinone (TNP‑2092) delivered via intra‑articular injection alongside systemic antibiotics for periprosthetic joint infection (PJI) in China.
Key Results
The open‑label study enrolled 10 patients. Seven met microbiological criteria (culture or next‑generation sequencing confirmation of Gram‑positive infection) and were included in the efficacy analysis. Among five patients with early or acute PJI who completed six months of follow‑up, all were reported as treatment successes; four of these patients reached 12 months and remained successful. In the chronic PJI cohort, two patients completed six months of follow‑up and one achieved treatment success; 12‑month data for the chronic subgroup were not yet available.
Safety
Safety was assessed in nine patients and no treatment‑emergent adverse events (TEAEs) or serious adverse events (SAEs) were attributed to TNP‑2092. The tenth patient remained under observation at the cut‑off date and had reported no TNP‑2092‑related adverse events to that point.
Interpretation and Next Steps
TenNor described TNP‑2092 as a first‑in‑class, triple‑targeting agent aimed at implant‑associated biofilm infections. Following the Phase IIa results, the company has initiated a multi‑centre Phase IIb trial after receiving approval from China’s National Medical Products Administration (NMPA). The Phase IIa data are hypothesis‑generating: the small sample size (POC trial of 10 patients, seven evaluable for efficacy) limits definitive conclusions and highlights the need for larger, controlled studies to confirm efficacy and safety.
Principal investigator: Professor Li Cao, chief physician, Orthopedics Center, Xinjiang Medical University First Affiliated Hospital, led the POC trial and commented on the potential for intra‑articular TNP‑2092 to reduce the need for extensive surgical interventions in PJI.
Regulatory Context
TNP‑2092 has previously received Qualified Infectious Disease Product (QIDP), Fast Track, and Orphan Drug designations from the US Food and Drug Administration for PJI. Separately, TenNor reported in November 2024 that a Phase III trial of another candidate, rifasutenizol, met all primary endpoints versus standard of care.
Bottom Line
The Phase IIa results are promising, particularly for early/acute PJI, but are preliminary. Confirmation in larger, randomized trials is required before TNP‑2092 can be considered a change in standard practice.
Help us improve.
